ARTICLE SUMMARY:
In many election cycles, the third quarter preceding Election Day produces a flurry of M&A and financing activity in anticipation of post-election uncertainty. Our analysis of this year’s Q3 results indicates that this is yet another area where this year’s election campaign proves to be the exception, rather than the rule, with only limited medtech dealmaking and financing activity.
Throughout the first half of 2016, medical device companies took some solace in knowing that, while the IPO window had apparently closed again after several years of revitalized activity, M&A remained strong.
